<DOC>
	<DOCNO>NCT00792610</DOCNO>
	<brief_summary>At time present study , necessity booster vaccination prevention hepatitis B ( HB ) 15 year post-vaccination group young adult become seronegative HB marker complete neonatal HB vaccination question . A booster vaccination strategy may lead significant economic impact national health care resource , costs/benefits must therefore carefully evaluate . Unfortunately , data support analyse lack . Because increase risk HB infection anticipate adolescent enter young adulthood become sexual active , breakthrough infection fulminant HB might main concern instead risk chronic HB carriage . To address issue , study aim measure booster response HB vaccination seronegative young adult complete neonatal HB vaccine Taiwan .</brief_summary>
	<brief_title>The Hepatitis B Vaccine Booster Response Among Youth Who Had Completed Neonatal Hepatitis B Vaccines</brief_title>
	<detailed_description>This cohort study conduct October 2007 Jan 2009 . The target population subject age 18-23 year born 1984 Taiwanese national HB vaccination program launch . Their vaccination record must show complete neonatal HB vaccination , seronegative three HB viral marker include HBsAg ( Hepatitis B surface antigen ) , anti-HBc ( core antibody Hepatitis B ) , anti-HBs ( Surface antibody Hepatitis B ) within 2 year entry study study entry . They recruit Student 's Health Center Clinic referral , Bulletin Board System post , Web-broadcast invitation . The neonatal HB vaccination record verify linkage Taiwan Center Disease Control databank . Signed informed consent obtain participant parent guardian . Pregnant female , person previous history allergy HB vaccine , allergy yeast exclude . First 3 month screen phase recruit college student assay hepatitis B viral marker . Seronegative subject approach enrollment receive hepatitis B vaccine booster afterwards . All participant test HB marker enrollment , even test previous month , confirm status . A questionnaire complete enrolment record sociodemographic factor include age , gender , self report family history hepatitis B carrier , self report blood type , . The participant receive three intramuscular dos HB vaccine ( Engerix-B , recombinant hepatitis B surface antigen , 20 microgram/ml/vial , GlaxoSmithKline , Belgium ) baseline 1st 6th month follow-up visit . Their anti-HBs status check baseline , 7-10 day , 1 month , 6 month , 7 month follow first dose HB vaccine . Adverse effect associate vaccine also report within one week Engerix-B injection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. aged 1823 year 2. youth bear July 1984 receive hepatitis B virus marker checkup within 2 year include HBsAg , core antibody hepatitis B ( antiHBc ) , surface antibody hepatitis B ( antiHBs ) result negative 3 viral marker . 3 . Participants agree sign inform consent . For young 20 year old subject , one parent also help participate review sign inform consent . 4 . Participants willing receive 3 dos Hepatitis B vaccine without payment . 5 . General condition good health judge doctor 1 . Allergy Hepatitis B vaccine yeast 2. pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>youth</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>vaccination</keyword>
	<keyword>booster</keyword>
	<keyword>immunity response</keyword>
</DOC>